Study confirms GSK-Vir antibody drug reduces hospitalization, death in COVID-19 patients

GlaxoSmithKline Plc and Vir Biotechnology said on Monday final results from a late-stage study of their monoclonal antibody confirmed it significantly reduced hospitalization and death among high-risk COVID-19 patients when given early in the disease.

The treatment, sotrovimab, received an emergency use authorization from the U.S. Food and Drug Administration in May, while the European Union's drug regulator has also backed it. The drugmakers also said on Monday the U.S. National Institutes of Health (NIH) has recommended sotrovimab to treat high-risk, non-hospitalized patients with mild-to-moderate COVID-19.